Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jul 10;12(1):53–76. doi: 10.1111/j.1527-3458.2006.00053.x

A New Look at the 5α‐Reductase Inhibitor Finasteride

Deborah A Finn 1,✉, Amy S Beadles‐Bohling 1, Ethan H Beckley 1, Matthew M Ford 1, Katherine R Gililland 1, Rebecca E Gorin‐Meyer 1, Kristine M Wiren 1
PMCID: PMC6741762  PMID: 16834758

Abstract

Finasteride is the first 5α‐reductase inhibitor that received clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). These clinical applications are based on the ability of finasteride to inhibit the Type II isoform of the 5α‐reductase enzyme, which is the predominant form in human prostate and hair follicles, and the concomitant reduction of testosterone to dihydrotestosterone (DHT). In addition to catalyzing the rate‐limiting step in the reduction of testosterone, both isoforms of the 5α‐reductase enzyme are responsible for the reduction of progesterone and deoxycorticosterone to dihydroprogesterone (DHP) and dihydrodeoxycorticosterone (DHDOC), respectively. Recent preclinical data indicate that the subsequent 3α‐reduction of DHT, DHP and DHDOC produces steroid metabolites with rapid non‐genomic effects on brain function and behavior, primarily via an enhancement of γ‐aminobutyric acid (GABA)ergic inhibitory neurotransmission. Consistent with their ability to enhance the action of GABA at GABAA receptors, these steroid derivatives (termed neuroactive steroids) possess anticonvulsant, antidepressant and anxiolytic effects in addition to altering aspects of sexual‐ and alcohol‐related behaviors. Thus, finasteride, which inhibits both isoforms of 5α‐reductase in rodents, has been used as a tool to manipulate neuroactive steroid levels and determine the impact on behavior. Results of some preclinical studies and clinical observations with finasteride are described in this review article. The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdrawal.

Keywords: Alcohol withdrawal, Allopregnanolone, Depression, Epilepsy, Finasteride, Neuroactive steroids, Seizure susceptibility, Sexual behavior

Full Text

The Full Text of this article is available as a PDF (150.5 KB).

REFERENCES

  • 1. Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002;29: 665–669. [DOI] [PubMed] [Google Scholar]
  • 2. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5α‐reductase 2 gene in male pseudo‐hermaphroditism. Nature 1991;354: 159–161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α‐reductases. Proc Natl Acad Sci USA 1990;87: 3640–3644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α‐reductase inhibitors in the treatment of benign pro static hyperplasia. J Urol 2004;172: 1399–1403. [DOI] [PubMed] [Google Scholar]
  • 5. Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG, Harris GS. Inhibition of rat á‐reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997;61: 55–64. [DOI] [PubMed] [Google Scholar]
  • 6. Barbaccia ML, Affricano D, Trabucchi M, et al. Ethanol markedly increases “GABAergic” neurosteroids in alcohol‐preferring rats. Eur J Pharmacol 1999;384: R1–2. [DOI] [PubMed] [Google Scholar]
  • 7. Bayram F, Muderris I, Guven M, Ozcelik B, Kelestimur F. Low‐dose (2.5 mg/day) finasteride treatment in hirsutism. Gynecol Endocrinol 2003;17: 419–422. [DOI] [PubMed] [Google Scholar]
  • 8. Belelli D, Lambert JJ. Neurosteroids: Endogenous regulators of the GABAA receptor. Nat Rev Neurosci 2005;6: 565–575. [DOI] [PubMed] [Google Scholar]
  • 9. Bergeson SE, Warren RK, Crabbe JC, Metten P, Erwin VG, Belknap JK. Chromosomal loci influencing chronic alcohol withdrawal severity. Mamm Genome 2003;14: 454–463. [DOI] [PubMed] [Google Scholar]
  • 10. Birzniece V, Backstrom T, Johansson IM, et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Brain Res Rev 2005[epub, ahead of print]. [DOI] [PubMed] [Google Scholar]
  • 11. Bitran D, Dugan M, Renda P, Ellis R, Foley M. Anxiolytic effects of the neuroactive steroid pregnanolone (3α‐OH‐5 β‐pregnan‐20‐one) after microinjection in the dorsal hippocampus and lateral septum. Brain Res 1999;850: 217–224. [DOI] [PubMed] [Google Scholar]
  • 12. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopreg‐nanolone at brain GABAA receptors. J Neuroendocrinol 1995;7: 171–177. [DOI] [PubMed] [Google Scholar]
  • 13. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995;52: 113–133. [DOI] [PubMed] [Google Scholar]
  • 14. Brot MD, Akwa Y, Purdy RH, Koob GF, Britton KT. The anxiolytic‐like effects of the neurosteroid allopre‐gnanolone: Interactions with GABAA receptors. Eur J Pharmacol 1997;325: 1–7. [DOI] [PubMed] [Google Scholar]
  • 15. Brunet M, Rodamilans M, Martinez‐Osaba MJ, et al. Effects of long‐term antiepileptic therapy on the catab‐olism of testosterone. Pharmacol Toxicol 1995;76: 371–375. [DOI] [PubMed] [Google Scholar]
  • 16. Cagetti E, Liang J, Spigelman I, Olsen RW. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GAB AA receptors. Mol Pharmacol 2003;63: 53–64. [DOI] [PubMed] [Google Scholar]
  • 17. Cagetti E, Pinna G, Guidotti A, Baicy K, Olsen RW. Chronic intermittent ethanol (CIE) administration in rats decreases levels of neurosteroids in hippocampus, accompanied by altered behavioral responses to neurosteroids and memory function. Neuropharmacology 2004;46: 570–579. [DOI] [PubMed] [Google Scholar]
  • 18. Carlin JR, Hoglund P, Eriksson LO, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 1992;20: 148–155. [PubMed] [Google Scholar]
  • 19. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002;57: 231–234. [DOI] [PubMed] [Google Scholar]
  • 20. Celotti F, Negri‐Cesi P, Poletti A. Steroid metabolism in the mammalian brain: 5α‐Reduction and aromatiza‐tion. Brain Res Bull 1997;44: 365–75. [DOI] [PubMed] [Google Scholar]
  • 21. Cilotti A, Danza G, Serio M. Clinical application of 5α‐reductase inhibitors. J Endocrinol Invest 2001;24: 199–203. [DOI] [PubMed] [Google Scholar]
  • 22. Ciotta L, Cianci A, Calogero AE, et al. Clinical and endocrine effects of finasteride, a 5α‐reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995;64: 299–306. [DOI] [PubMed] [Google Scholar]
  • 23. Clifford GM, Farmer RD. Drug or symptom‐induced depression in men treated with α1‐blockers for benign prostatic hyperplasia? A nested case‐control study. Pharmacoepidemiol Drug Safety 2002;11: 55–61. [DOI] [PubMed] [Google Scholar]
  • 24. Concas A, Mostallino MC, Porcu P, et al. Role of brain allopregnanolone in the plasticity of γ‐aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 1998;95: 13284–13289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Crabbe JC. Provisional mapping of quantitative trait loci for chronic ethanol withdrawal severity in BXD recombinant inbred mice. J Pharmacol Exp Ther 1998;286: 263–271. [PubMed] [Google Scholar]
  • 26. Crabbe, JC, Jr. , Young, ER , Kosobud A. Genetic correlations with ethanol withdrawal severity. Pharmacol Biochem Behav 1983;18(Suppl 1):541–547. [DOI] [PubMed] [Google Scholar]
  • 27. Criswell HE, Breese GR. A conceptualization of integrated actions of ethanol contributing to its GABAmimetic profile: A commentary. Neuropsychopharmacology 2005;30: 1407–1425. [DOI] [PubMed] [Google Scholar]
  • 28. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5α‐reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79: 703–706. [DOI] [PubMed] [Google Scholar]
  • 29. Dazzi L, Serra M, Seu E, et al. Progesterone enhances ethanol‐induced modulation of mesocortical dopamine neurons: Antagonism by finasteride. J Neurochem 2002;83: 1103–1109. [DOI] [PubMed] [Google Scholar]
  • 30. Edinger KL, Frye CA. Testosterone's analgesic, anxiolytic, and cognitive‐enhancing effects may be due in part to actions of its 5α‐reduced metabolites in the hippocampus. Behav Neurosci 2004;118: 1352–1364. [DOI] [PubMed] [Google Scholar]
  • 31. Ellis JA, Panagiotopoulos S, Akdeniz A, Jerums G, Harrap SB. Androgenic correlates of genetic variation in the gene encoding 5α‐reductase type 1. J Hum Genet 2005;50: 534–537. [DOI] [PubMed] [Google Scholar]
  • 32. Feder HH. Hormones and sexual behavior. Annu Rev Psychol 1984;35: 165–200. [DOI] [PubMed] [Google Scholar]
  • 33. Finn DA, Beadles‐Bohling AS, Tanchuck MA, Gililland KR, Mark GP. The hippocampus is an important brain site necessary for the anticonvulsant effect of allopregnanolone in WSP‐1 mice. Alcohol Clin Exp Res 2005;29: 95A. [Google Scholar]
  • 34. Finn DA, Ford MM, Wiren KM, Roselli CE, Crabbe JC. The role of pregnane neurosteroids in ethanol withdrawal: Behavioral genetic approaches. Pharmacol Ther 2004;101: 91–112. [DOI] [PubMed] [Google Scholar]
  • 35. Finn DA, Long SL, Tanchuck MA, Crabbe JC. Interaction of chronic ethanol exposure and finasteride: Sex and strain differences. Pharmacol Biochem Behav 2004;78: 435–443. [DOI] [PubMed] [Google Scholar]
  • 36. Finn DA, Sinnott RS, Ford MM, Long SL, Tanchuck MA, Phillips TJ. Sex differences in the effect of ethanol injection and consumption on brain allopregnanolone levels in C57BL/6 mice. Neuroscience 2004;123: 813–819. [DOI] [PubMed] [Google Scholar]
  • 37. Follesa P, Biggio F, Caria S, Gorini G, Biggio G. Modulation of GABAA receptor gene expression by allopregnanolone and ethanol. Eur J Pharmacol 2004;500: 413–425. [DOI] [PubMed] [Google Scholar]
  • 38. Ford MM, Nickel JD, Finn DA. Treatment with and withdrawal from finasteride alter ethanol intake patterns in male C57BL/6J mice: Potential role of endogenous neurosteroids Alcohol 2005;37: 23–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Freeman EW, Frye CA, Rickels K, Martin PA, Smith SS. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002;22: 516–520. [DOI] [PubMed] [Google Scholar]
  • 40. Frye CA. The role of neurosteroids and nongenomic effects of progestins in the ventral tegmental area in mediating sexual receptivity of rodents. Horm Behav 2001;40: 226–233. [DOI] [PubMed] [Google Scholar]
  • 41. Frye CA, Bayon LE. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3α,5α‐THP. Neuroendocrinology 1998;68: 272–280. [DOI] [PubMed] [Google Scholar]
  • 42. Frye CA, Bayon LE, Pursnani NK, Purdy RH. The neurosteroids, progesterone and 3α,5α‐THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 1998;808: 72–83. [DOI] [PubMed] [Google Scholar]
  • 43. Frye CA, Murphy RE, Platek SM. Anti‐sense oligonucleotides, for progestin receptors in the VMH and glutamic acid decarboxylase in the VTA, attenuate progesterone‐induced lordosis in hamsters and rats. Behav Brain Res 2000;115: 55–64. [DOI] [PubMed] [Google Scholar]
  • 44. Frye CA, Reed TA. Androgenic neurosteroids: Anti‐seizure effects in an animal model of epilepsy. Psychoneuroendocrinology 1998;23: 385–399. [DOI] [PubMed] [Google Scholar]
  • 45. Frye CA, Rhodes ME. Progesterone's 5α‐reduced metabolite, 3α,5α‐THP, mediates lateral displacement of hamsters. Brain Res 2005;1038: 59–68. [DOI] [PubMed] [Google Scholar]
  • 46. Frye CA, Scalise TJ, Bayon LE. Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J Neuroendocrinol 1998;10: 291–296. [DOI] [PubMed] [Google Scholar]
  • 47. Frye CA, Vongher JM. Progestins' rapid facilitation of lordosis when applied to the ventral tegmentum corresponds to efficacy at enhancing GABAA receptor activity. J Neuroendocrinol 1999;11: 829–837. [DOI] [PubMed] [Google Scholar]
  • 48. Frye CA, Vongher JM. Progesterone and 3α,5α‐THP enhance sexual receptivity in mice. Behav Neurosci 2001;115: 1118–1128. [PubMed] [Google Scholar]
  • 49. Frye CA, Vongher JM. Ventral tegmental area infusions of inhibitors of the biosynthesis and metabolism of 3α,5α‐THP attenuate lordosis of hormone‐primed and behavioural oestrous rats and hamsters. J Neuroendocrinol 2001;13: 1076–1086. [DOI] [PubMed] [Google Scholar]
  • 50. Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav 2002;41: 306–315. [DOI] [PubMed] [Google Scholar]
  • 51. Frye CA, Walf AA. Hippocampal 3α,5α‐THP may alter depressive behavior of pregnant and lactating rats. Pharmacol Biochem Behav 2004;78: 531–540. [DOI] [PubMed] [Google Scholar]
  • 52. Gabriel KI, Cunningham CL, Finn DA. Allopregnanolone does not influence ethanol‐induced conditioned place preference in DBA/2J mice. Psychopharmacology (Berl) 2004;176: 50–56. [DOI] [PubMed] [Google Scholar]
  • 53. Gasior M, Carter RB, Witkin JM. Neuroactive steroids: Potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci 1999;20: 107–112. [DOI] [PubMed] [Google Scholar]
  • 54. Gee KW, McCauley LD, Lan NC. A putative receptor for neurosteroids on the GABAA receptor complex: The pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 1995;9: 207–227. [PubMed] [Google Scholar]
  • 55. Geller J. Effect of finasteride, a 5α‐reductase inhibitor on prostate tissue androgens and prostate‐specific antigen. JClin Endocrinol Metab 1990;71: 1552–1555. [DOI] [PubMed] [Google Scholar]
  • 56. Gilman DP, Hitt JC. Effects of gonadal hormones on pacing of sexual contacts by female rats. Behav Biol 1978;24: 77–87. [DOI] [PubMed] [Google Scholar]
  • 57. Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E. Effects of finasteride on health‐related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. Prostate 1996;29: 83–90. [DOI] [PubMed] [Google Scholar]
  • 58. Gisleskog PO, Hermann D, Hammarlund‐Udenaes M, Karlsson MO. A model for the turnover of dihydro‐testosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998;64: 636–647. [DOI] [PubMed] [Google Scholar]
  • 59. Gorin‐Meyer RE, Wiren KM, Tanchuck MA, Long SL, Finn DA. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6. J and DBA/2J mice. submitted. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Gorin RE, Crabbe JC, Tanchuck MA, Long SL, Finn DA. Effects of finasteride on chronic and acute ethanol withdrawal severity in the WSP and WSR selected lines. Alcohol Clin Exp Res 2005;29: 939–948. [DOI] [PubMed] [Google Scholar]
  • 61. Gormley GJ. Finasteride: A clinical review. Biomed Pharmacother 1995;49: 319–24. [DOI] [PubMed] [Google Scholar]
  • 62. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK‐906), a 5α‐reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70: 1136–1141. [DOI] [PubMed] [Google Scholar]
  • 63. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999;96: 13512–13517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 1998;139: 2–19. [DOI] [PubMed] [Google Scholar]
  • 65. Guarna A, Danza G, Bartolucci G, Marrucci A, Dini S, Serio M. Synthesis of 5,6,6‐[2H3]finasteride and quantitative determination of finasteride in human plasma at picogram level by an isotope‐dilution mass spectrometric method. J Chromatogr B Biomed Appl 1995;674: 197–204. [DOI] [PubMed] [Google Scholar]
  • 66. Guarna A, Occhiato EG, Danza G, Conti A, Serio M. 5α‐reductase inhibitors, chemical and clinical models. Steroids 1998;63: 355–361. [DOI] [PubMed] [Google Scholar]
  • 67. Harrison NL, Simmonds MA. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res 1984;323: 287–292. [DOI] [PubMed] [Google Scholar]
  • 68. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003;53: 390–391. [DOI] [PubMed] [Google Scholar]
  • 69. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38: 1082–1088. [DOI] [PubMed] [Google Scholar]
  • 70. Hill M, Popov P, Havlikova H, et al. Altered profiles of serum neuroactive steroids in premenopausal women treated for alcohol addiction. Steroids 2005;70: 515–524. [DOI] [PubMed] [Google Scholar]
  • 71. Hill M, Popov P, Havlikova H, et al. Reinstatement of serum pregnanolone isomers and progesterone during alcohol detoxification therapy in premenopausal women. Alcohol Clin Exp Res 2005;29: 1010–1017. [DOI] [PubMed] [Google Scholar]
  • 72. Hirani K, Khisti RT, Chopde CT. Behavioral action of ethanol in Porsolt's forced swim test: Modulation by 3α‐hydroxy‐5α‐pregnan‐20‐one. Neuropharmacology 2002;43: 1339–1350. [DOI] [PubMed] [Google Scholar]
  • 73. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT. Evaluation of GABAergic neuroactive steroid 3α‐hydroxy‐5α‐pregnane‐20‐one as a neurobiological substrate for the anti‐anxiety effect of ethanol in rats. Psychopharmacology (Berl) 2005;180: 267–278. [DOI] [PubMed] [Google Scholar]
  • 74. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85: 4650–4656. [DOI] [PubMed] [Google Scholar]
  • 75. Jain NS, Hirani K, Chopde CT. Reversal of caffeine‐induced anxiety by neurosteroid 3α‐hydroxy‐5α‐preg‐nane‐20‐one in rats. Neuropharmacology 2005;48: 627–638. [DOI] [PubMed] [Google Scholar]
  • 76. Kaminski RM, Marini H, Kim WJ, Rogawski MA. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia 2005;46: 819–827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Kaufman KD, Dawber RP. Finasteride, a Type 2 5α‐reductase inhibitor, in the treatment of men with androgenetic alopecia. Exp Opin Invest Drugs 1999;8: 403–15. [DOI] [PubMed] [Google Scholar]
  • 78. Kenny B, Ballard S, Blagg J, Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 1997;40: 1293–1315. [DOI] [PubMed] [Google Scholar]
  • 79. Khisti RT, Chopde CT, Jain SP. Antidepressant‐like effect of the neurosteroid 3α‐hydroxy‐5α‐pregnane‐20‐one in mice forced swim test. Pharmacol Biochem Behav 2000;67: 137–143. [DOI] [PubMed] [Google Scholar]
  • 80. Khisti RT, VanDoren MJ, Matthews DB, Morrow AL. Ethanol‐induced elevation of 3α‐hydroxy‐5α‐preg‐nane‐20‐one does not modulate motor incoordination in rats. Alcohol Clin Exp Res 2004;28: 1249–1256. [DOI] [PubMed] [Google Scholar]
  • 81. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: The prostate cancer prevention trial revisited. J Clin Oncol 2005;23: 7460–7466. [DOI] [PubMed] [Google Scholar]
  • 82. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5α‐reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999;288: 679–684. [PubMed] [Google Scholar]
  • 83. Kosobud A, Crabbe JC. Ethanol withdrawal in mice bred to be genetically prone or resistant to ethanol withdrawal seizures. J Pharmacol Exp Ther 1986;238: 170–177. [PubMed] [Google Scholar]
  • 84. Le Melledo, JM , Baker G. Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother 2004;4: 851–860. [DOI] [PubMed] [Google Scholar]
  • 85. Lephart ED. Age‐related changes in brain and pituitary 5α‐reductase with finasteride (Proscar) treatment. Neurobiol Aging 1995;16: 647–650. [DOI] [PubMed] [Google Scholar]
  • 86. Lephart ED, Ladle DR, Jacobson NA, Rhees RW. Inhibition of brain 5α‐reductase in pregnant rats: Effects on enzymatic and behavioral activity. Brain Res 1996;739: 356–360. [DOI] [PubMed] [Google Scholar]
  • 87. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother 2004;5: 933–940. [DOI] [PubMed] [Google Scholar]
  • 88. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother 2005;3: 103–114. [DOI] [PubMed] [Google Scholar]
  • 89. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003;79: 942–946. [DOI] [PubMed] [Google Scholar]
  • 90. Majewska MD. Neurosteroids: Endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992;38: 379–395. [DOI] [PubMed] [Google Scholar]
  • 91. Marberger MJ. Long‐term effects of finasteride in patients with benign prostatic hyperplasia: A double‐blind, placebo‐controlled, multicenter study. PROWESS Study Group. Urology 1998;51: 677–686. [DOI] [PubMed] [Google Scholar]
  • 92. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α‐reduc‐tase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74: 505–508. [DOI] [PubMed] [Google Scholar]
  • 93. McEwen BS. Non‐genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991;12: 141–147. [DOI] [PubMed] [Google Scholar]
  • 94. Mellon SH, Vaudry H. Biosynthesis of neurosteroids and regulation of their synthesis. Int Rev Neurobiol 2001;46: 33–78. [DOI] [PubMed] [Google Scholar]
  • 95. Morrow AL, Janis GC, VanDoren MJ, et al. Neurosteroids mediate pharmacological effects of ethanol: A new mechanism of ethanol action Alcohol Clin Exp Res 1999;23: 1933–1940. [DOI] [PubMed] [Google Scholar]
  • 96. Moss ML, Kuzmic P, Stuart JD, et al. Inhibition of human steroid 5α reductases type I and II by 6‐aza‐steroids: Structural determinants of one‐step vs two‐step mechanism. Biochemistry 1996;35: 3457–3464. [DOI] [PubMed] [Google Scholar]
  • 97. Muderris, II , Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73: 984–987. [DOI] [PubMed] [Google Scholar]
  • 98. Neubauer BL, Gray HM, Hanke CW, et al. LY191704 inhibits type I steroid 5α‐reductase in human scalp. J Clin Endocrinol Metab 1996;81: 2055–2060. [DOI] [PubMed] [Google Scholar]
  • 99. Newmark ME, Penry JK. Catamenial epilepsy: A review. Epilepsia 1980;21: 281–300. [DOI] [PubMed] [Google Scholar]
  • 100. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5α‐androst‐1‐ene‐17β‐carboxamide, a new type of specific competitive inhibitor of testosterone 5α‐reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16: 15–21. [DOI] [PubMed] [Google Scholar]
  • 101. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52: 301–311. [DOI] [PubMed] [Google Scholar]
  • 102. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6: 2311–2322. [PubMed] [Google Scholar]
  • 103. Peričiá D, Svob D, Jazvinšćak M, Mirkovic K. Anticonvulsive effect of swim stress in mice. Pharmacol Biochem Behav 2000;66: 879–886. [DOI] [PubMed] [Google Scholar]
  • 104. Pierucci‐Lagha A, Covault J, Feinn R, et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 2005;30: 1193–1203. [DOI] [PubMed] [Google Scholar]
  • 105. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: A pilot study. Psychooncology 2002;11: 518–23. [DOI] [PubMed] [Google Scholar]
  • 106. Purdy RH, Morrow AL, Moore, PH, Jr. , Paul, SM. Stress‐induced elevations of γ‐aminobutyric acid type A receptor‐active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88: 4553–4557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress‐sensitive conditions Trends Pharmacol Sci 2003;24: 103–106. [DOI] [PubMed] [Google Scholar]
  • 108. Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 2004;62: 99–118. [DOI] [PubMed] [Google Scholar]
  • 109. Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α‐androstanediol and 17β‐estradiol. Neuroscience 2004;129: 195–207. [DOI] [PubMed] [Google Scholar]
  • 110. Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004;310: 230–239. [DOI] [PubMed] [Google Scholar]
  • 111. Reddy DS, O'Malley BW, Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005;48: 14–24. [DOI] [PubMed] [Google Scholar]
  • 112. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000;294: 909–915. [PubMed] [Google Scholar]
  • 113. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001;42: 337–344. [DOI] [PubMed] [Google Scholar]
  • 114. Reddy DS, Rogawski MA. Stress‐induced deoxycorticosterone‐derived neurosteroids modulate GABAA receptor function and seizure susceptibility. J Neurosci 2002;22: 3795–3805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Rhodes ME, Frye CA. Attenuating 5α‐pregnane‐3α‐ol‐20‐one formation in the hippocampus of female rats increases pentylenetetrazole‐induced seizures. Epilepsy Behav 2005;6: 140–146. [DOI] [PubMed] [Google Scholar]
  • 116. Rittmaster RS. 5α‐reductase inhibitors. J Androl 1997;18: 582–587. [PubMed] [Google Scholar]
  • 117. Rittmaster RS, Stoner E, Thompson DL, Nance D, Lasseter KC. Effect of MK‐906, a specific 5α‐reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989;10: 259–262. [DOI] [PubMed] [Google Scholar]
  • 118. Romeo E, Brancati A, De Lorenzo A, et al. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clin Neuropharmacol 1996;19: 366–369. [DOI] [PubMed] [Google Scholar]
  • 119. Romeo E, Pompili E, Di Michele, F , et al. Effects of fluoxetine, indomethacine and placebo on 3α,5α‐tetra‐hydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry 2000;1: 101–104. [DOI] [PubMed] [Google Scholar]
  • 120. Romeo E, Strohle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155: 910–913. [DOI] [PubMed] [Google Scholar]
  • 121. Rosciszewska D, Buntner B, Guz I, Zawisza L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986;49: 47–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Roy AK, Chatterjee B. Androgen action. Crit Rev Eukaryot Gene Exp 1995;5: 157–76. [DOI] [PubMed] [Google Scholar]
  • 123. Rupprecht R, Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22: 410–416. [DOI] [PubMed] [Google Scholar]
  • 124. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001;75: 496–500. [DOI] [PubMed] [Google Scholar]
  • 125. Sanna E, Talani G, Busonero F, et al. Brain steroidogenesis mediates ethanol modulation of GABAA receptor activity in rat hippocampus. J Neurosci 2004;24: 6521–6530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Schanzer W. Metabolism of anabolic androgenic steroids. Clin Chem 1996;42: 1001–1020. [PubMed] [Google Scholar]
  • 127. Schule C, Romeo E, Uzunov DP, et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3α‐hydroxysteroid dehydrogenase activity. Mol Psychiatry 2006;11: 261–272. [DOI] [PubMed] [Google Scholar]
  • 128. Seyle H. The anesthetic effect of steroid hormones. Proc Soc Exp Biol Med 1941;46: 116–121. [Google Scholar]
  • 129. Smith SS, Gong QH, Hsu FC, Markowitz RS, Ffrench‐Mullen JM, Li X. GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998;392: 926–930. [DOI] [PubMed] [Google Scholar]
  • 130. Smith SS, Gong QH, Li X, et al. Withdrawal from 3α‐OH‐5α‐pregnan‐20—One using a pseudopregnancy model alters the kinetics of hippocampal GABAA‐gated current and increases the GABAA receptor á4 sub‐unit in association with increased anxiety. J Neurosci 1998;18: 5275–5284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the mouse results in anxio‐genic effects of 3α,5β‐THP: A possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl) 2005: 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996;30: 16–27. [DOI] [PubMed] [Google Scholar]
  • 133. Stoner E. The clinical development of a 5α‐reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37: 375–378. [DOI] [PubMed] [Google Scholar]
  • 134. Strohle A, Romeo E, Hermann B, et al. Concentrations of 3α‐reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999;45: 274–277. [DOI] [PubMed] [Google Scholar]
  • 135. Stuart JD, Lee FW, Simpson Noel, D , et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α‐reductases: Determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol 2001;62: 933–942. [DOI] [PubMed] [Google Scholar]
  • 136. Sudduth SL, Koronkowski MJ. Finasteride: The first 5α‐reductase inhibitor. Pharmacotherapy 1993;13: 309–329. [PubMed] [Google Scholar]
  • 137. Tartagni M, Schonauer MM, Cicinelli E, et al. Intermittent low‐dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril 2004;82: 752–755. [DOI] [PubMed] [Google Scholar]
  • 138. Tennent BJ, Smith ER, Davidson JM. The effects of estrogen and progesterone on female rat proceptive behavior. Horm Behav 1980;14: 65–75. [DOI] [PubMed] [Google Scholar]
  • 139. Thigpen AE, Russell DW. Four‐amino acid segment in steroid 5α‐reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 1992;267: 8577–8583. [PubMed] [Google Scholar]
  • 140. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α‐reductase isozyme expression. J Clin Invest 1993;92: 903–910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349: 215–224. [DOI] [PubMed] [Google Scholar]
  • 142. Titus MA, Gregory CW, Ford, OH , 3rd, Schell, MJ , Maygarden SJ, Mohler JL. Steroid 5α‐reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11: 4365–4371. [DOI] [PubMed] [Google Scholar]
  • 143. Torres JM, Ortega E. Alcohol intoxication increases allopregnanolone levels in female adolescent humans. Neuropsychopharmacology 2003;28: 1207–1209. [DOI] [PubMed] [Google Scholar]
  • 144. Torres JM, Ortega E. Alcohol intoxication increases allopregnanolone levels in male adolescent humans. Psychopharmacology (Berl) 2004;172: 352–355. [DOI] [PubMed] [Google Scholar]
  • 145. Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 2004;38: 1070–1073. [DOI] [PubMed] [Google Scholar]
  • 146. Trueb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209: 202–207. [DOI] [PubMed] [Google Scholar]
  • 147. Ugale RR, Mittal N, Hirani K, Chopde CT. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole‐induced seizures in mice. Brain Res 2004;1023: 102–111. [DOI] [PubMed] [Google Scholar]
  • 148. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95: 3239–3244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149. Van Luijtelaar G, Budziszewska B, Tetich M, Lason W. Finasteride inhibits the progesterone‐induced spike‐wave discharges in a genetic model of absence epilepsy. Pharmacol Biochem Behav 2003;75: 889–894. [DOI] [PubMed] [Google Scholar]
  • 150. Van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: Association with measures of cognition and well‐being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology 2001;26: 591–612. [DOI] [PubMed] [Google Scholar]
  • 151. VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL. Neuroactive steroid 3α‐hydroxy‐5α‐pregnan‐20‐one modulates electrophysiological and behavioral actions of ethanol. J Neurosci 2000;20: 1982–1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152. Walf AA, Sumida K, Frye CA. Inhibiting 5α‐reductase in the amygdala attenuates antianxiety and anti‐depressive behavior of naturally receptive and hormone‐primed ovariectomized rats. Psychopharmacology (Berl) 2005: 1–10 [Oct 12, epub]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: Effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 1999;30: 264–288. [DOI] [PubMed] [Google Scholar]
  • 154. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost‐effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005;118: 850–857. [DOI] [PubMed] [Google Scholar]
  • 155. Zimmerberg B, Brunelli SA, Fluty AJ, Frye CA. Differences in affective behaviors and hippocampal allopregnanolone levels in adult rats of lines selectively bred for infantile vocalizations. Behav Brain Res 2005;159: 301–311. [DOI] [PubMed] [Google Scholar]
  • 156. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phy‐totherapeutic agent (Permixon®), Tamsulosin or Finasteride. Eur Urol 2005;48: 269–276. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES